




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : B01J 31/18, C07F 13/00 C07D 303/48		A1	(11) International Publication Number: WO 94/03271
			(43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/GB93/01666		(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).	
(22) International Filing Date: 5 August 1993 (05.08.93)			
(30) Priority data: 9216662.8 6 August 1992 (06.08.92) GB 9308968.8 30 April 1993 (30.04.93) GB		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BELL, David [GB/GB]; MILLER, David [GB/GB]; ATTRILL, Robin, Patrick [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			

(54) Title: CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY



(57) Abstract

A compound of formula (I), in which M is a transition metal ion; A is a counter-ion if required; r, s and t are independently 0 to 3 such that r+s+t is in the range of 1 to 3; R^a, R^b, R^c are each independently hydrogen or CH₂OR' where R' is hydrogen or an organic group; B and E are independently oxygen, CH₂, NR^d in which R^d is alkyl, hydrogen, alkylcarbonyl, or arylcarbonyl or SO_n where n is 0 or an integer 1 or 2, with the proviso that B and E are not simultaneously CH₂ and that when B is oxygen, NR^d or SO_n, then r cannot be 0, and when E is oxygen, NR^d or SO_n, then t cannot be 0; R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently hydrogen, alkyl or alkoxy.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY

This invention relates to novel catalysts and their use in the conversion of certain olefins into chirally enriched epoxides.

5 WO/91/14694 describes certain catalysts of the following formula (A):




in which

M is a transition metal ion, A is an anion, and n is either 0, 1 or 2. At least one of X₁ or X₂ is selected from the group consisting of silyls, aryls, secondary alkyls and tertiary alkyls; and at least one of X₃ or X₄ is selected from the same group. Y₁, Y₂, Y₃, Y₄, Y₅ and Y₆ are independently selected from the group consisting of hydrogen, halides, alkyls, aryl groups, silyl groups, and alkyl groups bearing heteroatoms such as alkoxy and halide. Also, at least one of R₁, R₂, R₃ and R₄ is selected from a first group consisting of H, CH₃, C₂H₅ and primary alkyls. Furthermore, if R₁ is selected from said first group, then R₂ and R₃ are selected from a second group consisting of aryl groups, heteroatom-bearing aromatic groups, secondary alkyls and tertiary alkyls. If R₂ is selected from said first group, then R₁ and R₄ are selected from said second group. If R₃ is selected from said first group, then R₁ and R₄ are selected from said second group. If R₄ is selected from said first group, then R₂ and R₃ are selected from said second group.

Such catalysts are described as being useful in enantioselectively epoxidising a prochiral olefin.

Structurally distinct catalysts have now been prepared which surprisingly possess the ability to catalyse the enantioselective epoxidation of certain prochiral olefins.

Accordingly, the present invention provides a compound of formula (I):



in which M is a transition metal ion;

5 A is a counter-ion if required;

r, s and t are independently 0 to 3 such that r+s+t is in the range of 1 to 3;

R^a, R^b, R^c are each independently hydrogen or CH₂OR' where R' is hydrogen or an organic group;

10 B and E are independently oxygen, CH₂, NR^d in which R^d is alkyl, hydrogen, alkylcarbonyl, or arylcarbonyl or SO_n where n is 0 or an integer 1 or 2, with the proviso that B and E are not simultaneously CH₂ and that when B is oxygen, NR^d or SO_n, then r cannot be 0, and when E is oxygen, NR^d or SO_n, then t cannot be 0;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently hydrogen, alkyl or alkoxy.

15 Suitable transition metal ions, M, include Mn, Cr, Fe, Ni, Co, Ti, V, Ru and Os in an appropriate oxidation state.

Preferably the transition metal ion, M, is Mn in oxidation state (II) or (III).

It should be appreciated that in some cases for example when M is Mn (II), a counter-ion is not required.

20 Suitable counter-ions, A, include those anions mentioned in WO 91/14694.

Preferably, A is chloride.

Suitable organic groups R' include alkyl, alkylcarbonyl, arylcarbonyl or aryl derivatives.

Particular examples of R' include substituted alkyl groups.

25 One example of R' is triphenylmethyl.

Preferably s and t are zero, r is 1 and R^a is hydrogen, B is oxygen and E is CH₂; or r, s and t are 1, R^a, R^b and R^c are hydrogen and B and E are both oxygen; or s is zero, r and t are both 1, R^a is hydrogen or triphenylmethyloxymethylene and R^c

is hydrogen, B is oxygen and E is $-\text{CH}_2-$; or r and t are both 1, s is zero, R^a and R^c are hydrogen, B is NR^d where R^d is phenyl carbonyl and E is CH_2 .

Suitably, R_2 , R_4 , R_5 and R_7 each independently represent hydrogen.

Suitably R_1 , R_3 , R_6 and R_8 each independently represent C_{1-6} alkyl.

5 Favourably R_1 and R_8 represent branched alkyl groups such as tertiary alkyl groups.

R_3 and R_6 also advantageously represent branched alkyl groups.

One preferred example for each of R_1 and R_8 is tertiary butyl.

Particular examples of R_3 and R_6 are tertiary butyl and methyl.

10 Examples of R_2 , R_4 , R_5 and R_7 are hydrogen.

The term 'alkyl' when used alone or when forming part of other groups (for example alkoxy groups or alkylcarbonyl groups) includes straight- or branched-chain alkyl groups containing 1 to 12 carbon atoms, suitably 1 to 6 carbon atoms, examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl group.

15 When used herein the term 'aryl' includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, alkylcarbonyl and phenylcarbonyl.

A preferred aryl group is a substituted or unsubstituted phenyl group.


Transition metals M include those having oxidation states of (II) or more.

20 Suitable substituents for aryl include alkyl, halogen and alkoxy.

Optional substituents for alkyl groups include those mentioned herein for aryl groups, phenyl is a particular example.

It should be appreciated that the carbon atoms marked with an asterisk are chiral centres and the present invention extends to each individual enantiomer and any
25 mixtures thereof.

The present invention also provides a process for the preparation of compounds of formula (I) which comprises forming a transition metal complex of the following compound of formula (II):




where variables R_1 to R_{10} , B, E, r , s , t , R^a , R^b and R^c are as defined in relation to formula (I), and thereafter if necessary separating any enantiomers.


Suitably the transition metal ion complex may be formed by the addition of a
 5 suitable transition metal salt such as manganese (II) or (III) acetate, preferably manganese (III) acetate, to a compound of formula (II) in a suitable solvent such as ethanol or methylene dichloride, at elevated temperature. The optional replacement or interconversion of the counter ion may be effected by the addition of an alkali metal salt containing the desired counter-ion such as LiCl.

10 The separation of any enantiomers may be carried out by conventional techniques, such as crystallisation of derivatives or chromatography. However, it should be appreciated that it is preferred that separation of enantiomers is carried out before forming a transition metal complex.


The invention further provides a process for the preparation of compounds of
 15 formula (II) which comprises condensing sequentially, in any order, a compound of formula (III):



where r , s , t , R^a , R^b and R^c , B, E are as defined in formula (I) and R_{11} and R_{12} independently represent hydrogen or an amine protecting group, providing at least
 20 one of R_{11} and R_{12} is hydrogen, with a compound of formula (IV);





and a compound of formula (V), removing any protecting group R₁₁ or R₁₂ as necessary;



- 5 wherein R₁ to R₁₀ are as defined in relation to formula (I), and thereafter as required isolating the required compound including if necessary separating any enantiomers.

It is preferred that the compound of formula (II) is prepared from optically pure compounds of formula (III) which are preferably prepared themselves from optically pure starting materials. Alternatively, racemates or mixtures of enantiomers of formula (II) or (III) may themselves be resolved using conventional techniques in the art such as crystallisation of derivatives, or chromatography.

When compounds of formula (II) are required in which one or more of R₁, R₂, R₃, R₄ and R₉ are not the same as one or more of R₈, R₇, R₆, R₅ and R₁₀ respectively, then compounds of formula (III) may be sequentially condensed with compounds of formula (IV) and formula (V), in any order, by heating a suitably protected compound of formula (III) with a compound of formula (IV) or (V) (in a 1:1 mole ratio) in an inert solvent such as ethanol, if necessary, purifying the resulting intermediate compound of formula (VI) or (VII):




wherein variables R_1 to R_{12} , r , s , t , R^a , R^b , R^c , E and B are as defined in to formula (III), (IV) and (V) using conventional techniques such as chromatography removing any R_{11} or R_{12} protecting groups and then repeating the reaction using a compound of formula (IV) or (V) as required.

Suitable protecting groups R_{11} or R_{12} include conventional amine protecting groups such as benzyl groups, silyl groups or acyl groups such as benzoyl groups.


The removal of R_{11} or R_{12} when representing protecting groups may be carried out using conventional techniques in the art depending upon the nature of the protecting group.

It should be appreciated that when each of R_1 , R_2 , R_3 , R_4 and R_9 is the same as each of R_8 , R_7 , R_6 , R_5 and R_{10} respectively the compounds of formula (IV) and (V) are the same, therefore, compounds of formula (III) in which R_{11} and R_{12} is hydrogen are preferably used and two moles of a compound of formula (IV) or (V) are utilised, in an inert solvent, such as ethanol, at elevated temperature, for example at reflux.

Compounds of formula (III) are either known compounds or may be prepared according to known methods or analogously to known methods or analogously to the methods described herein, for example when a compound of formula (III) is : 3,4-diaminotetrahydrofuran, such a compound may be prepared according to the following scheme, for example, as described in descriptions 1 and 2.



Alternatively, 3,4-diaminotetrahydrofuran may be prepared according to the following scheme, for example, as described in descriptions 4 to 6.



5 The 5R, 6R-diamino-1,3-dioxepane may be prepared according to the procedures, as described in descriptions 8 to 13.

The 3R, 4S-diamino tetrahydropyran may be prepared according to the procedures as described in descriptions 15 to 17.

10 The 3R,4R-diamino-(2R)(triphenyl methoxymethyl)tetrahydrofuran may be prepared according to the procedures as described in descriptions 21 to 24.

The (±) trans-1-benzoyl-3,4-diaminopiperidine may be prepared according to the procedures as described in descriptions 25 to 27.

15 Compounds of formula (IV) and (V) are either commercially available, are known compounds or may be prepared according to known methods or analogously to known methods for examples such as these described by G.Casiraghi et al J. Chem Soc. Perkin Transactions I. 1980 P1862 - 1865.

Novel compounds of formula (II), (III), (IV), (V), (VI) and (VII) form an aspect of the present invention.

It should be appreciated that the term chiral catalyst refers to catalysts of formula (I) which have a predominance of one particular enantiomer and therefore are useful in forming a predominance of one particular enantiomer of the resulting epoxide produced from a prochiral olefin.

- 5 It should be appreciated that the catalysts, of formula (I) are preferably prepared in a chiral form by using a resolved compound of formula (III) which may be resolved using conventional techniques. The compound of formula (III) may itself be prepared from suitable precursor compounds such as these outlined in hereinbefore which may be resolved using conventional techniques or may be purchased in a
10 resolved form. Alternatively, the coupled compound of formula (II) may be resolved using conventional techniques.

The invention further provides a process for enantioselectively epoxidising a prochiral olefin in the presence of an oxygen source and a chiral catalyst of formula (I).

- 15 Suitable prochiral olefins include compounds which comprise the following groups as part of their structure, cyclohexene, 5,6-dihydro-2H-pyran, 1,2,5,6-tetrahydropyridine, 1,2,3,4-tetrahydropyridine and 5,6-dihydro-2H-thiopyran.

- Favoured prochiral olefins include those compounds which comprise the following groups as part of their structure form: 1,2-dihydronaphthalene, 2H-
20 chromene, 1,2-dihydroquinoline, 1,2-dihydroisoquinoline and 2H-thiochromene.

Such compounds are well known in the potassium channel activator field.

Preferably, prochiral olefins include those mentioned in EP-A-0 376 524, such as the compounds of formula (XIV) therein, and in particular 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran.

- 25 It should be appreciated that the present invention particularly extends to the preparation of all epoxide precursors to those compounds of formula (I) in EP-A-0 376 524 and especially the specific examples thereof using the herein described process.

- 30 The present invention also particularly extends to the subsequent conversion of all epoxide precursors to all specific examples in EP-A-0 376 524, to those specific examples in particular to the preparation of (-)-trans-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol.

Suitable oxygen sources include sodium hypochlorite.

- 35 It should be appreciated that only one enantiomer of a catalyst of formula (I) is required to produce the 3S,4S enantiomer of the epoxide precursor to compounds described in EP-A-0 376 524 which in turn produce the 3S,4R configuration in the compounds of formula (I) as described in EP-A-0 376 524. Conversely, the 3R, 4R enantiomers of the epoxide precursors produce the 3R, 4S configuration in the compounds of formula (I) as described in EP-A-0376 524.

The following descriptions and examples illustrate the present invention.

Description 1**(±) 2,5-Dihydro-3-nitro furan (D1)**

- A mixture of (±) *trans* 3-chloromercuro-4-nitro-2,5-dihydrofuran¹ (38.54g, 109.6 mmol) and Et₃N (11.07g, 109.6 mmol) in CH₂Cl₂ (2.2L) at 25°C was stirred for 1.25h. 5% aqueous citric acid (1.1L) was added and stirring was continued for 5 min. The mixture was filtered through celite, separated and the organic phase washed with 5% aqueous citric acid (220 ml), dried over Na₂SO₄ and concentrated *in vacuo*. Chromatography of the residue on silica (Merck 9385, 300g) eluting with CHCl₃-Hexane (1:1 -> 1:0) afforded (D1) as a pale yellow oil which crystallised in the freezer, 5.45g (43.2%).

δ (CDCl₃) 4.95 (4H,s) and 7.10 (1H,s)

1. P. Bitha and Y - I. Lin, J. Heterocyclic Chem., 1988, 25, 1035-1036.

15 Description 2**(±) 3,4-Diaminotetrahydrofuran (D2)**

- A solution of (±) 4-amino-3-nitrotetrahydrofuran, prepared from (D1) via the method of Bitha and Lin¹, (4.66g, 35.3 mmol) in EtOH (100 ml) containing 10% palladium on carbon (2.5g) was hydrogenated on a Parr shaker apparatus at 35 psi for 65h at 20°C. The suspension was filtered, the solids washed with EtOH (100 ml) and the combined filtrate evaporated *in vacuo* to afford (±) (D2) as a colourless oil, 3.26g (81.5%)

δ (CDCl₃) 1.40 (4H,bs), 3.20 (2H, m), 3.50 (2H,dd) and 4.08 (2H,dd).

25 Description 3**(±) 3,4-bis (3-*tert*-Butyl-5-methylsalicylideamino)tetrahydrofuran (D3)**

- A solution of the racemic diamine (D2) (855 mg, 8.38 mmol) and 3-*tert*-butyl-5-methylsalicylaldehyde (3.22g, 16.76 mmol) in EtOH (50 ml) was heated at reflux for 1.5h. The solvent was removed *in vacuo* and the residue chromatographed on silica (Merck 9385, 300g) using CHCl₃ as eluent to afford (±) (D3) as pale yellow needles, 1.35g, (35.8%).

δ (CDCl₃) 1.42 (18H,s), 2.25 (6H,s), 3.95-4.10 (2H,m), 4.43 (2H,q), 6.90 (2H,d), 7.15 (2H,d), 8.30 (2H,s) and 13.10 (2H,bs).

35 Description 4**(S,S) *trans* 3,4-bis(methanesulphonyloxy)tetrahydrofuran (D4)**

- A solution of 1,4-anhydro-L-threitol (2.45g, 23.5 mmol) (ex Aldrich Chemical company) in a mixture of THF (75 ml) and Et₂O (75 ml) at 0°C was treated sequentially with triethylamine (7.2 ml, 51.7 mmol, 2.2 eq) and methanesulphonyl

chloride (3.82 ml, 49.35 mmol, 2.1 eq). The mixture was stirred for 4h then stored at 0°C overnight (~16h).

The reaction was filtered and the solids washed with THF (20 ml). The combined filtrate was evaporated *in vacuo* and partitioned between 10% aqueous citric acid (60 ml) and EtOAc (150 ml). The organic phase was dried (MgSO₄) and evaporated to afford (D4) as a colourless oil, 5.82g (95%).

δ (CDCl₃) 3.12 (6H,s) 4.00 (2H,dd), 4.18 (2H,dd) and 5.25 (2H,dd).

Description 5

10 (S,S) *trans* 3,4-Diazidotetrahydrofuran (D5)

A mixture of the dimesylate (D4) (5.80g, 22.3 mmol) and lithium azide (5.46, 111.5 mmol, 2.5 eq) in DMSO (60 ml) was heated at 100-110°C for 40h. After cooling to ambient the reaction was diluted with water (1L) and extracted with EtOAc (1L, 2 x 0.75L). The combined organic phase was washed with water (0.5L) and brine (0.5L), dried over MgSO₄ and evaporated *in vacuo* to a pale yellow oil of the title compound, 2.18g (61.5%).

δ (CDCl₃) 3.75 (2H,dd) and 3.90 - 4.05 (4H,m).

Description 6

20 (S,S) *trans* 3,4-Diaminotetrahydrofuran

To lithium aluminium hydride (2.05g, 54 mmol) in dry THF (150 ml) at 0°C was added the diazide (D5) (2.08g, 13.5 mmol) in THF (50 ml) dropwise over 10 min. After 15 min the solution was allowed to warm to ambient, then stirred for 16h.

The reaction mixture was re-cooled to 0°C and quenched sequentially with H₂O (2 ml), 15% aqueous NaOH (2 ml) and further H₂O (6 ml) and warmed to ambient. After stirring for 1h the mixture was filtered through celite, rinsed with THF (2 x 150 ml) and the combined filtrate evaporated *in vacuo* to afford (D6) as a pale yellow oil, 1.28g (93%).

δ (CDCl₃) 1.30 (4H,bs), 3.20 (2H,dd), 3.50 (2H,dd) and 4.08 (2H,dd).

30

Description 7

(S,S) *trans* 3,4-bis(3-*tert*-Butyl-5-methylsalicylideamino)tetrahydrofuran (D7)

A solution of the (S,S)-diamine (D6) (1.26g, 12.35 mmol) and 3-*tert*-butyl-5-methylsalicylaldehyde (4.74g, 24.70 mmol) in EtOH (75 ml) was heated at reflux for 3.5h. The solution was cooled and solvent removed *in vacuo* to afford crude (5) as a yellow oil, 5.50g (99%).

A sample of the crude material (4.55g) was chromatographed on silica (Merck 9385, gradient of CHCl₃ in hexane) to afford pure (D7) as a yellow foam, 4.39g (95.5% yield).

δ (CDCl_3) 1.42 (18H,s), 2.25 (6H,s), 3.95 - 4.10 (4H,m) 4.33 (2H,q), 6.90 (2H,d), 7.15 (2H,d), 8.30 (2H,s) and 13.15 (2H,bs).

Description 8

5 (2R,3R)-1,4-Dibenzyloxy-2,3-dimethanesulfonyloxybutane

To a solution of (2R,3R)-(+)-1,4-dibenzyloxy-2,3-butanediol (25.3g, 83.7mmol ex Aldrich Chemical Company) in dichloromethane (165ml), cooled in an ice bath, was added methanesulfonyl chloride (13.0ml, 167.4 mmol), followed by slow addition of triethylamine (23.3ml, 167.4mmol) such that the temperature did not rise above 5°C. Once the addition was complete the reaction was allowed to stir with ice-bath cooling for 3 hours. Water (600ml) was then added and the organic phase separated. The aqueous phase was re-extracted with dichloromethane (200ml) and the combined organic phases washed with water (400ml) and brine (400ml), dried (MgSO_4), and the solvent evaporated to afford a pale yellow solid. Trituration with diethyl ether afforded the title compound (28.2g, 74%) as colourless crystals m.p. 72-73°C.

^1H n.m.r. (CDCl_3): δ 3.03 (s, 6H, 2xCH₃), 3.76 (m, 4H, 2xCH₂O), 4.48 (d, 2H, CH₂Ph), 4.57 (d, 2H, CH₂Ph), 5.00 (m, 2H, 2xCH), 7.27-7.39 (m, 10H, 2xPh)

^{13}C n.m.r. (CDCl_3): δ 38.8 (2xCH₃), 68.7 (2xCH₂), 73.7 (2xCH₂), 78.7 (2xCH), 128.1, 128.2, 128.6, 137.0 (2xPh).

EI-MS: m/e 459 (MH^+), 367 ($\text{M}^+ - \text{CH}_2\text{Ph}$).

$\text{C}_{20}\text{H}_{26}\text{O}_8\text{S}_2$ requires: C: 52.39, H: 5.72%.

found : C: 52.36, H: 5.59%.

25 Description 9

(2R,3R)-Dimethanesulfonyloxybutane-1,4-diol

(2R,3R)-1,4-Dibenzyloxy-2,3-dimethanesulfonyloxybutane (27.6g, 60.3mmol) (D8) was dissolved in acetone (500ml), a suspension of 10% Pd/C (29.9g) in acetone (300ml) added, and the mixture hydrogenated at 1 atm. pressure for 2 hours at ambient temperature. The mixture was then filtered three times through a pad of silica and Celite, and the solvent evaporated to give the title compound as a straw-coloured oil (14.7g, 87%), which solidified on standing.

^1H n.m.r. ($\text{DMSO}-d_6$): δ 3.24 (s, 6H, 2xCH₃), 3.69 (m, 4H, 2xCH₂), 4.76 (m, 2H, 2xCH), 5.33 (t, 2H, 2xOH).

^{13}C n.m.r. ($\text{DMSO}-d_6$): δ 38.1 (2xCH₃), 59.7 (2xCH₂), 80.3 (2xCH).

EI-MS: m/e 279 (MH^+), 261 ($\text{MH}^+ - \text{H}_2\text{O}$), 183 ($\text{M}^+ - \text{OMs}$), 165 ($\text{M}^+ - \text{OMs}, \text{H}_2\text{O}$).

Description 10**(6R,7R)-Dimethanesulfonyloxy-2,4,9,11-tetraoxadodecane**

(2R,3R)-Dimethanesulfonyloxybutane-1,4-diol (14.7g, 52.9 mmol) (D9) was dissolved in dimethoxymethane (89.5ml) and dichloromethane (30ml) at 40°C.

- 5 Lithium bromide (0.91g) and p-toluenesulfonic acid monohydrate (1.01g, 5.29mmol) were added, and the mixture heated under reflux for 3 hours. The reaction was allowed to cool to ambient temperature, and then poured into saturated sodium bicarbonate solution (200ml), extracted with ethyl acetate (2x200ml), dried (MgSO₄) and evaporated to give a colourless oil. This was purified by column chromatography
10 on silica, eluting with 0-1% methanol in dichloromethane, to afford the title compound as a colourless oil (8.2g, 42%).

¹H n.m.r. (CDCl₃): δ 3.13 (s, 6H, 2xCH₃), 3.39 (s, 6H, 2xOCH₃), 3.87 (m, 4H, 2xCH₂), 4.66 (m, 4H, 2xOCH₂O), 5.02 (m, 2H, 2xCH).

- ¹³C n.m.r. (CDCl₃): δ 38.8 (2xSCH₃), 55.8 (2xOCH₃), 66.1 (2xCH₂), 78.4
15 (2xCH), 96.8 (2xOCH₂O)

CI-MS: m/e 384 (MNH₄⁺).

C₁₀H₂₂O₁₀S₂ requires: C: 32.78, H: 6.05%.

found : C: 32.22, H: 5.62%.

20 Description 11**(5R,6R)-Dimethanesulfonyloxy-1,3-dioxepane**

- A solution of (6R,7R)-dimethanesulfonyloxy-2,4,9,11-tetraoxadodecane (8.2g, 22.4mmol) (D10) and p-toluenesulfonic acid monohydrate (0.26g, 1.34mmol) in toluene (165ml) was heated under reflux overnight. The solvent was evaporated
25 and the brown residue triturated with diethyl ether to afford the title compound as an off-white solid (5.9g, 91%) m.p. 133-134°C.

¹H n.m.r. (CDCl₃): δ 3.13 (s, 6H, 2xCH₃), 3.84 (m, 2H, CH₂), 4.06 (m, 2H, CH₂), 4.77 (s, 2H, OCH₂O), 4.81 (m, 2H, 2xCH).

- ¹³C n.m.r. (CDCl₃): δ 38.8 (2xCH₃), 64.1 (2xCH₂), 78.3 (2xCH), 94.6
30 (OCH₂O)

EI-MS: m/e 291 (MNH⁺), 195 (M⁺-OMs).

C₇H₁₄O₈S₂ requires: C: 28.96, H: 4.86%.

found : C: 29.22, H: 4.61%.

35 Description 12**(5R,6R)-Diazido-1,3-dioxepane**

A mixture of (5R,6R)-dimethanesulfonyloxy-1,3-dioxepane (5.0g, 17.2mmol) D11 and lithium azide (4.2g, 86mmol) in dimethylsulphoxide (60ml) was stirred and heated to 110-120°C overnight. The reaction mixture was then cooled, poured into

water (200ml), and extracted with ethyl acetate (2x150ml). The combined organic phases were washed with water (2x150ml) and brine (150ml), dried (MgSO₄) and evaporated to give the title compound as a brown oil (2.7g, 85%).

¹H n.m.r. (CDCl₃): δ 3.49 (m, 2H, 2xCH), 3.74 (m, 2H, 2xCH₂), 3.93 (m, 2H, CH₂), 4.73 (s, 2H, OCH₂O).

¹³C n.m.r. (CDCl₃): δ 64.3 (2xCH), 64.6 (2xCH₂) 94.3 (OCH₂O).

EI-MS: m/e 185 (MH⁺), 157 (MH⁺-N₂), 142 (M⁺-N₃).

C₅H₈N₆O₂ requires: C: 32.61, H: 4.38, N: 45.63%.

found : C: 32.33, H: 4.67, N: 45.38%.

10

Description 13

(5R,6R)-Diamino-1,3-dioxepane

To a slurry of lithium aluminium hydride (2.1g, 55.3mmol) in dry tetrahydrofuran (70ml) at 0°C under an argon atmosphere was added dropwise a solution of (5R, 6R)-Diazido-1,3-dioxepane (2.6g, 14.1mmol) (D12) in dry tetrahydrofuran (50ml). During the addition the reaction temperature was maintained below 10°C with an ice-salt bath. One completion, the reaction mixture was allowed to warm to ambient temperature, and stirred for a further 1.5 hours. It was then re-cooled and the reaction quenched by addition of water (2ml), 2M NaOH (2ml), and water (4ml), the temperature again being maintained below 10°C by means of an ice-salt bath. The quenched reaction mixture was allowed to warm to ambient temperature, stirred for a further 2 hours, then filtered through Celite, and the filter pad washed well with tetrahydrofuran. The combined filtrates were evaporated to afford the title compound as a pale yellow oil (1.3g, 70%).

¹H n.m.r. (CDCl₃): δ 1.56 (brs, 4H, 2xNH₃), 2.62 (m, 2H, 2xCH), 3.58 (m, 2H, CH₂), 3.77 (m, 2H, 2xCH₂), 4.72 (s, 2H, OCH₂O)

¹³C n.m.r. (CDCl₃): δ 57.9 (2xCH), 67.5 (2xCH₂) 93.8 (OCH₂O).

C₅H₁₂N₂O₂ requires: C: 45.44, H: 9.15, N: 21.20%.

found : C: 45.13, H: 8.76, N: 19.58%.

30

EI-MS: m/e 133 (MH⁺), 116 (M⁺-NH₂)⁺, 90 (M-2NH₂)⁺.

Description 14**Preparation f (5R,6R)-Di-(3,5-di-tert-butyl) salicylidenamino-1,3-dioxepane**

(5R,6R)-Diamino-1,3-dioxepane (1.0g, 7.6mmol) (D13) and 3,5-di-tert-butylsalicylaldehyde (3.6g, 15.4mmol, 2eq.) were dissolved in ethanol (100ml), and the solution stirred under reflux for 3 hours. The reaction mixture was then allowed to cool, the solvent was evaporated, and the residue purified by column chromatography on silica, eluting with 4% diethyl ether in hexane. This afforded the title compound as a bright yellow foam (3.5g, 82%).

¹H n.m.r. (CDCl₃): δ 1.23 (s, 18H, 6xCH₃), 1.41 (s, 18H, 6xCH₃), 3.85 (m, 2H, CH₂), 4.07 (m, 2H, CH₂), 4.87 (s, 2H, OCH₂O), 6.99 (d, 2H, Ar), 7.33 (d, 2H, Ar), 8.33 (s, 2H, 2xCH=N), 13.20 (brs, 2H, 2xOH).

¹³C n.m.r. (CDCl₃): δ 29.4 (6xCH₃), 31.4 (6xCH₃), 34.1 (2xCCH₃), 35.0 (2xCCH₃), 67.7 (2xCH), 73.8 (2xCH₂), 94.2 (OCH₂O), 117.6, 126.4, 127.4, 136.6, 140.3, 157.9 (Ar), 168.4 (2xC=N)

C₃₅H₅₂N₂O₄ requires: C: 74.43, H: 9.28, N: 4.96%.

found : C: 74.56, H: 9.15, N: 4.92%.

CI-MS: m/e 565 (MH⁺).

20 Description 15**(3R, 4R)-Diacetoxytetrahydropyran (D15)**

A solution of 3,4-di-O-acetyl-D-Xylal (11.16g) in 50% aqueous ethanol (400ml) containing PtO₂ (400mg) was hydrogenated at atmospheric pressure for 3.5 hours at 25°C. The suspension was filtered through celite, washed with 50% aqueous ethanol (50ml) and water (50ml), and the combined filtrate evaporated in vacuo to afford the title compound as a colourless oil, 9.6g (85%).

δ (CDCl₃): 1.30-1.50 (1H, m), 2.10 (6H, s), 2.10-2.20 (1H, m), 3.35-3.60 (2H, m), 3.80-4.00 (2H, m) and 4.80-5.00 (2H, m).

2. Dictionary of Organic Compounds, 5th Edition, 1982, Chapman & Hall, London, 579 and references therein.

Description 16**(3R,4R)-Dimethanesulfonyloxytetrahydropyran(D16)**

Sodium (~50mg) was dissolved in methanol (100ml) at ambient. To the resulting solution was added a solution of the diester (D15) (9.56g, 47.3mmol) in methanol (100ml) and the mixture stirred for 72 hours. Amberlite IR 120H⁺ resin (20g) was added and the mixture filtered. Concentration of the filtrate in vacuo afforded the diol as a colourless oil. This was dissolved in a mixture of tetrahydrofuran (220ml) and diethyl ether (220ml). Triethylamine (10.86g,

107.5mmol,) was added and the solution cooled to 0°C. Methanesulphonyl chloride (11.76g, 102.7mmol) was added dropwise at 0°C, the solution was stirred for a further hour then stored at 4°C for 16 hours. The resulting suspension was filtered and the solids washed with tetrahydrofuran (2x95ml) and diethyl ether (2x180ml).

- 5 The combined filtrate was evaporated in vacuo and the residue partitioned between ethyl acetate (200ml) and 10% aqueous citric acid (200ml). The organic phase was dried (MgSO₄), filtered and concentrated in vacuo to a colourless foam to afford the title compound, 12.07g (93%).

10 δ (CDCl₃): 3.10 (6H,s), 2.00-2.40 (2H,m), 3.40-4.20 (4H,m), 4.55-4.65 (1H,m) and 4.70-4.85 (1H,m).

Description 17

(3R,4S)-Diaminotetrahydropyran (D17)

- 15 The dimesylate (D16) (12.07g, 44 mmol) was dissolved in dimethylsulphoxide (88ml) and treated with lithium azide (10.8g, 220mmol). The mixture was heated at 100°C for 40 hours, then cooled to ambient and poured into water (1.03L) and extracted with ethyl acetate (1.03L, 2 x 0.59L). The combined organic phase was washed with water (300ml) and brine (300ml), dried over MgSO₄ and concentrated in vacuo to give the crude diazide as a brown oil, 3.7g. This was
- 20 dissolved in tetrahydrofuran (45ml), and added dropwise to a cold (0°C) suspension of lithium aluminium hydride (3.34g, 88mmol) in tetrahydrofuran (220ml), maintaining the temperature below +10°C. After completion of addition the suspension was stirred at 0°C for 0.5 hours then warmed to ambient and stirred for 16 hours.

- 25 The mixture was recooled to 0°C and quenched sequentially with water (3.34ml) in tetrahydrofuran (5ml), 15% aqueous sodium hydroxide (3.34ml) and further water (10ml). The mixture was allowed to warm to ambient, stirred for one hour then filtered through celite, rinsing with tetrahydrofuran (2x400ml). The combined filtrate was concentrated in vacuo to give the title diamine (3) as a
- 30 colourless oil, 2.62g (51%).

δ (CDCl₃): 1.20-1.90 (6H,m), 2.40-2.50 (2H,m), 2.90-3.40 (2H,m) and 3.80-4.00 (2H,m).

Description 18**(3R,4S)-bis-(3,5-Di-tert-Butylsalicylideamino)tetrahydropyran, (D18)**

To the diamine (D17) (2.55g, 22mmol) in ethan 1 (220ml) was added 3,5-di-tertbutylsalicaldehyde (10.3g, 44mmol). The mixture was heated at reflux for 2 hours, cooled to ambient filtered, and the crystalline product dried in vacuo to afford the title compound as yellow crystals, 4.81g, (40%).

δ (CDCl₃): 1.20 (18H,s), 1.40 (18H,s), 1.50-2.20 (2H,m), 3.50-3.70 (4H,m), 4.00-4.15 (2H,m), 7.00 (2H,bs), 7.35 (2H,bs), 8.33 (1H,s), 8.37 (1H,s) and 13.20 (2H,bs).

Description 19**(3R,4S)-bis (3-tert-Butyl-5-methylsalicylideamino) tetrahydropyran (D19)**

A solution of the diamine (D17) (0.62g, 5.35mmol) and 3-tertbutyl-5-methylsalicaldehyde (2.05g, 10.7mmol) in ethanol (40ml) was heated at reflux for 2 hours. The solution was cooled then stored at 4°C for 70 hours to afford a yellow precipitate. This was filtered, washed with cold 95% aqueous ethanol (5ml) and dried in vacuo to afford the title compound, 1.22g (49%).

δ (CDCl₃): 1.40 (18H,s), 1.80-2.20 (2H,m), 2.20 (6H,s), 3.40-3.70 (4H,m), 4.00-4.20 (2H,m), 6.80 (2H,bs), 7.05 (2H,bs), 8.27 (1H,s), 8.30 (1H,s) and 13.30 (2H,bs).

Description 20**(3S,4S)-bis (3,5-di-tert-Butylsalicylideamino) tetrahydrofuran (D20)**

A solution of (S,S)-diamine (D6) (0.96g, 9.4mmol) and 3,5-di-tertbutylsalicaldehyde (4.4g, 18.8mmol) in ethanol (90ml) was heated at reflux for 2 hours. The mixture was cooled to 0°C, filtered and the solids washed with cold ethanol and dried to afford the title compound as yellow crystals, 3.07g (61%).

δ (CDCl₃): 1.27 (18H,s), 1.45 (18H,s), 3.95-4.10 (4H,m), 4.30-4.40 (2H,m), 7.05 (2H,d), 7.40 (2H,d), 8.35 (2H,s) and 13.20 (2H,s).

Description 21**(3S,4R)-Dihydroxy-(2R)-(hydroxymethyl)tetrahydropyran (D21)**

A solution of D-Glucal (16.0g, 0.11 mole) in 50% aqueous ethanol (500ml) was treated with platinum oxide (0.75g) and hydrogenated at ambient at atmospheric pressure for 5 hours. The suspension was treated with charcoal (50g) filtered through celite (200g) and the solids washed with 50% aqueous ethanol (300ml). The combined filtered was evaporated in vacu and dried over P₂O₅ to afford the title compound as a colourless oil, 16.0g (99%).

δ (CD₃OD): 1.50-1.70 (1H,m), 1.80-2.20 (1H,m), 3.00-3.20 (2H,m), 3.30-3.70 (3H,m), 3.80-4.00 (2H,m) and 4.90 (3H,bs)

3. Dicti nary of Organic Compounds, 5th Edition, 1982, Chapman and Hall, London, 2754, and references therein.

5

Description 22

(3S,4R)-Dihydroxy-(2R)-(triphenylmethoxymethyl) tetrahydropyran (D22)

A solution of the triol (D21) (1.76g, 11.9mmol) in pyridine (20ml) was treated with trityl chloride (3.31g, 11.9mmol) and 4-(dimethylamino)pyridine (50mg).

10 Diisopropylethylamine (1.92g, 14.8mmol, 1.25eq) was added and the solution stirred for 4 hour at ambient temperature.

The mixture was poured into water (200ml) and extracted with diethyl ether (2x200ml). The combined organic phase was washed with 10% aqueous citric acid (100ml) and brine (100ml), dried over MgSO₄ and concentrated in vacuo to an oil.

15 The residue was chromatographed on silica (eluent:gradient of methanol in chloroform) to afford the title compound as a colourless foam, 3.70g (79.7%).

δ (CDCl₃): 1.60-1.80 (1H,m), 1.90-2.00 (1H,m), 2.70 (2H,bs,D₂O exch), 3.25-3.50 (5H,m), 3.60-3.70 (1H,m), 3.90-4.00 (1H,m) and 7.20-7.50 (15H,m).

20 Description 23

(3R,4R)-Dimethanesulphonyloxy-(2R)-(triphenylmethoxymethyl)tetrahydropyran (D23)

To the diol (D22) (3.10g, 7.95mmol) in a mixture of diethyl ether and tetrahydrofuran (2:1, 150ml) was added triethylamine (1.76g, 17.5mmol). The mixture was cooled to 0°C and methanesulphonyl chloride (1.91g, 16.7mmol) added. After 2 hours the suspension was filtered and the filtrate concentrated in vacuo, then redissolved in ethyl acetate (200ml). The solution was washed with 10% aqueous citric acid (100ml) and brine (50ml), then dried over MgSO₄. Solvent was removed in vacuo and the residue dried to afford (12) as a colourless solid, 4.26g (95%).

30 δ (CDCl₃): 2.20-2.50 (2H,m), 2.50 (3H,s), 3.10 (3H,s), 3.20-3.30 (1H,m), 3.40-3.60 (3H,m), 3.95-4.10 (1H,m), 4.70-4.80 (2H,m) and 7.20-7.50 (15H,m).

Description 24

(3S,4S)-bis(3,5-Di-tert-butylsalicylideamino)-(2R)-(triphenylmethoxymethyl)tetrahydropyran (D24)

35 A mixture of the dimesylate (D23) (2.85g, 5.22mmol) and lithium azide (1.28g, 26.1mmol) in dimethyl sulphoxide (20ml) was heated at 100-110°C for 24 hour. The solution was cooled, poured into water (200ml) and extracted with ethyl acetate (2x300ml). The combined organic phase was washed with water (2x300ml)

and brine (300ml), and dried over MgSO_4 . Removal of the solvent afforded the intermediate diazide as a yellow foam (1.52g).

5 A 1.40g portion of the diazide in tetrahydrofuran (10ml) was added to a suspension of lithium aluminium hydride (470mg, 12.4mmol) in tetrahydrofuran (30ml) at 0°C . After stirring at 0°C for 1 hour the mixture was allowed to warm to ambient and stirred for 16 hours. The suspension was recooled to 0°C and quenched sequentially with water (0.5ml), 15% aqueous sodium hydroxide (0.5ml) and further water (1.5ml). After warming the ambient and stirring for 1 hour the mixture was filtered, the solids washed with tetrahydrofuran (2x20ml) and the combined filtrate
10 evaporated to afford the crude diamine as a foam (1.28g).

A portion of the diamine (1.18g) and 3,5-di-tert butylsalicylaldehyde (1.42g, 6.08mmol) in ethanol (30ml) was heated at reflux for 4 hour then cooled to ambient. Solvent was removed in *vacuo* and the residue chromatographed on silica (eluent: gradient of chloroform in hexane) to afford the title compound as a yellow powder,
15 210mg, in 8.4% overall yield from (D23).

δ (CDCl_3): 1.25 (9H,m), 1.30-1.60 (2H,m), 1.32 (9H,s), 1.40 (9H,s), 1.50 (9H,s), 2.40-2.55 (1H,s), 2.70-2.80 (1H,s), 3.30-3.60 (2H,m), 3.90-4.30 (3H,m), 6.85 (1H,bs), 7.00-7.35 (16H,m), 7.38 (1H,bs), 7.45 (1H,bs), 8.30 (1H,s), 8.50 (1H,s), 13.25 (1H,s) and 13.50 (1H,s).

20

Description 25

(\pm)trans-1-Benzoyl-3,4-bis(methanesulphonyloxy)piperidine (D25)

(\pm)trans-1-Benzoylpiperidine-3,4-diol (3g, 13.6mmol) was suspended in dichloromethane (70ml) and triethylamine (5.74ml, 43mmol) was added. The
25 mixture was cooled to -10°C and methanesulphonyl chloride (2.6ml, 34mmol) added over 5 min. After a further 15 min the mixture was poured into ice-water (50ml) and the organic layer washed with 5% aqueous citric acid (30ml). The solution was dried over MgSO_4 and concentrated in *vacuo* to a foam, 5.3g (100%).

δ_{H} (CDCl_3): 1.95 (2H,m), 2.30 (2H,m), 3.15 (6H,s), 4.70 (2H,m), 4.85 (2H,m)
30 and 7.45 (5H,m).

4. V. Petrow and O. Stephenson, J Pharm. Pharmacol, 1962, 14, 306-314.

Description 26

(\pm)trans-1-Benzoyl-3,4-diazidopiperidine (D26)

35 A mixture of the dimesylate (D25) (5.3g, 14mmol) and lithium azide (3.4g, 69mmol) in dimethylsulphoxide (36ml) was heated at 100°C for 18 hours. After cooling the reaction mixture was partitioned between dichloromethane (200ml) and water (50ml). The aqueous phase was separated and further extracted with dichloromethane (100ml, 50ml) and the combined organic extracts washed with water

(3x50ml), dried (Na_2SO_4) and concentrated in vacuo. The residue was chromatographed on silica (eluent: gradient of methanol in dichloromethane) to afford the title compound as a colourless solid, 900mg (24%).

5 δ_{H} (CDCl_3): 1.60 (2H,m), 2.10 (2H,m), 3.05 (2H,m), 3.20 (2H,m) and 7.40 (5H, m).

Description 27

(\pm)trans-1-Benzoyl-3,4-diaminopiperidine (D27)

10 A solution of the diazide (D26) (450mg, 1.7mmol) in ethanol (30ml) was treated with Lindlar catalyst (5%Pd/ CaCO_3 , 250mg) and stirred under hydrogen (1 atm) for 24 hour. The mixture was filtered and solvent removed in vacuo to afford the title compound as oil, 350mg (94%).

δ_{H} (DMSO): 1.20 (1H,m), 1.65-1.80 (2H,m), 2.20 (2H,m), 2.70 (1H,m), 3.00 (1H,m), 3.30 (1H,m), 4.40 (1H,m) and 7.40 (5H,m).

15

Description 28

(-)-trans-1-Benzoyl-3,4-bis(3,5-di-tert-butylsalicylideamino)piperidine (D28)

20 A solution of the amine (D27) (350mg, 1.6mmol) and 3,5-di-tertbutylsalicaldehyde (960mg, 4.1mmol) in ethanol (40ml) was heated at reflux for 3 hours. The mixture was cooled and filtered to afford the racemic bis-imine, 652mg (63%).

A 100mg sample was separated by chiral hplc (CHIRALPAK AD, eluent 2% ethanol in hexane) to afford the title compound as a single enantiomer, $[\alpha]_{\text{D}}^{25} = 228^\circ$ ($c=0.13$, CHCl_3).

25 δ_{H} (CDCl_3): 1.20 (18H,s), 1.45 (18H,s), 2.00 (2H,m), 3.25 (2H,m), 3.45 (1H,m), 3.55 (1H,m), 4.35 (2H,m), 6.95 (2H,s), 7.40 (7H,m), 8.30 (2H,s) and 13.15 (2H,bs).

Example 1

(±) 3,4-bis (3-*tert* Butyl-5-methylsalicylideamino) tetrahydrofuran manganese (III) chloride (E1)

- 5 A suspension of the racemic ligand (D3) (690 mg, 1.53 mmol) in EtOH (25 ml) was heated with Mn(OAc)₂·4H₂O (750 mg, 3.06 mmol) at reflux for 18h. LiCl (195 mg, 4.49 mmol) was added and reflux continued for a further 0.5h. Solvent was removed *in vacuo* and the residue chromatographed on silica (Merck 9385, 100g) eluting with a gradient of MeOH in CHCl₃, to afford the title compound
10 as a brown powder (90 mg, 11%) together with unreacted (D3), 420 mg (61% recovery).

Example 2

- 15 The epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using (E1) to give (±) 2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E2)

- Aqueous sodium hypochloride solution (16.75% w/v, 4.44 ml, 2 eq) was diluted to 12.5 ml with H₂O. 0.05M Na₂HPO₄ (aq) (5 ml) was added and the pH adjusted to 11.3. The resulting solution was cooled to 0°C and
20 added to a solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (1.39g, 5 mmol) and the catalyst (E1) (45 mg, 0.1 mmol, 2 mol%) in CH₂Cl₂ (5 ml). The mixture was stirred at 0°C for 1h then allowed to warm to room temperature and stirred for a further 16h.

- Hexane (50 ml) and H₂O (25 ml) were added and the organic layer separated.
25 The aqueous phase was washed with hexane (50 ml) and the combined organic phase dried over MgSO₄ and concentrated *in vacuo* to give a pale yellow oil, 1.42g.

- Quantitative hplc analysis showed this to contain 1.08g (74%) of the desired epoxide (E2) together with a trace (<5% recovery) of starting material both compounds identical (¹H nmr) with authentic samples.

30

Example 3

(S,S) *trans* 3,4-bis (3-*tert* Butyl-5-methylsalicylideamino)tetrahydrofuran manganese (III) chloride (E3)

Method A (using manganese (II) acetate)

- 35 A solution of (D7) (0.95g, 2.11 mmol) and Mn(OAc)₂·4H₂O (1.03g, 4.22 mmol) in EtOH (40 ml) was heated at reflux for 17h. Lithium chloride (268 mg, 6.33 mmol) was added and reflux continued for a further 0.5h. After cooling to ambient the solvent was removed *in vacuo* and the residue chromatographed on silica (Merck

9385, gradient of MeOH in CHCl_3) to afford (E3) as a brown powder, 26 mg (2.3%), together with unreacted (D7), 683 mg (72%).

Method B (using manganese (III) acetate)5.

- 5 A solution of (D7) (1.53g, 3.4 mmol) in a mixture of CH_2Cl_2 (17 ml) and MeOH (17 ml) was treated with $\text{Mn}(\text{OAc})_3 \cdot 2\text{H}_2\text{O}$ (0.01g, 3.4 mmol). The mixture was heated at reflux for 3h, cooled to ambient and treated with lithium chloride (0.21g, 5.1 mmol). After stirring for 16h the solvent was reduced *in vacuo* to ca. 8 ml, Et_2O (70 ml) was added and the suspension stirred for 1h. The mixture was filtered and the solids washed with Et_2O (3 x 20 ml) and dried *in vacuo* to afford (E3) as a brown powder, 1.57g (86%).

5 T. Matsushita and T. Shono, Bull. Chem. Soc. Japan, 1981, 54, 3743-3748.

Example 4

- 15 The chiral epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using (E3) to give (3R,4R)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E4)

- 20 Aqueous sodium hypochlorite solution (16.75% w/v, 8.9 ml 20.0 mmol) was diluted to 25 ml with H_2O . 0.05M NaH_2PO_4 (aq) (10 ml) was added and the pH adjusted to 11.3. The resulting solution was cooled to 0°C and added to a solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (2.78g, 10.0 mmol) and the catalyst (E3) (0.108g, 0.2 mmol, 2 mol%) in methylene chloride (10 ml). The mixture was stirred at 0°C for 1h then allowed to warm to room temperature and stirred for a further 20h.

- 25 Hexane (100 ml) and H_2O (50 ml) were added and the organic layer separated. The aqueous phase was washed with hexane (100 ml) and the combined organic phase dried over MgSO_4 and concentrated *in vacuo* to give a pale yellow oil, 2.86g.

- 30 Quantitative hplc analysis showed this to contain 2.09g, (71%) of the desired epoxide (E4) and a small quantity (about 10%) of starting material, both compounds identical (^1H NMR, TLC, HPLC) with authentic samples, e.e. = 66% by chiral HPLC.

Example 5

- 35 Preparation of (R,R)-5,6-bis-(3,5-di-tert-butylsalicylidenamino)-1,3-dioxepane]-manganese (III) chloride

(5R,6R)-Di-(3,5-di-tert-butyl)salicylidenamino-1,3-dioxepane (1.0g, 1.77mmol) (D14) and manganese (II) acetate tetrahydrate (2.17g, 8.87mmol) were suspended in 95% ethanol (50ml), and the mixture stirred under reflux overnight.

Lithium chloride (0.38g, 8.96mmol) was then added and heating continued for a further 30 minutes. The reaction mixture was then cooled, water (60ml) added, and filtered through Celite. The dark precipitate was washed well with water, then dissolved in dichloromethane (80ml), dried (MgSO_4), and the solvent evaporated to give the title compound as a dark brown solid (0.9g, 78%).

$\text{C}_{35}\text{H}_{50}\text{N}_2\text{O}_4\text{MnCl}$ requires: C:64.36, H:7.72, N:4.29%.

found: C: 64.57, H: 7.57, N: 4.09%

CI-MS: m/e 565 (MH-Mn,Cl^+), 235 (3,5-di-tert-butylsalicylaldehydeH) $^+$.

10 Example 6

Preparation of (3S,4S)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran by oxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using sodium hypochlorite catalysed by (R,R)-5,6-bis-(3,5-di-tert-butylsalicylidenamino)-1,3-dioxepane]-manganese (III) chloride

15 Sodium hypochlorite solution (11.4% w/v, 13.1ml, 2eq.) was diluted to 25ml with water, followed by the addition of 0.05 molar sodium dihydrogen phosphate (10ml). The pH of this solution was adjusted to 11.3 with 2 molar aqueous sodium hydroxide, and it was then added to a solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (2.78g, 10mmol), and (R,R)-[1,2-bis-(3,5-di-tert-butylsalicylidenamino)-1,3-dioxepane]-manganese (III) chloride (0.131g, 2mol%) in dichloromethane (10ml), which had been cooled in an ice bath. The reaction mixture was allowed to warm to ambient temperature and stirred for 22 hours, by which time the reaction was essentially complete.

The reaction mixture was diluted with water (50ml) and hexane (100ml), filtered through Celite, the organic phase separated and the aqueous extracted with a further portion of hexane (100ml). The combined organic phases were dried (MgSO_4) and evaporated to give the title compound as a yellowish solid (2.6g, 88%). Hplc determination of the chiral purity of the crude product gave an e.e. of 86.0%. The crude product was recrystallised from hexane to afford colourless crystals, m.p. 72-73°C.

^1H n.m.r. (CDCl_3): δ 1.29 (s, 3H, CH_3), 1.59 (s, 3H, CH_3), 3.53 (d, 1H, H-3), 3.94 (d, 1H, H-4), 6.90 (dd, 1H, H-8), 7.46 (dd, 1H, H-7), 7.57 (dd, 1H, H-5).

^{13}C n.m.r. (CDCl_3): δ 22.9 (CH_3), 25.5 (CH_3), 50.4 (C-3), 62.5 (C-4), 74.1 (C-2), 113.4 (tq, CF_3), 118.4 (C-8), 119.1 (qt, CF_2), 120.4 (C-4'), 121.1 (t, C-6), 128.1, 128.6 (2xt, C-5,7), 155.7 (C-8').

EI-MS: m/e 294 M^+ , 279 (M-CH_3) $^+$.

$\text{C}_{13}\text{H}_{11}\text{F}_5\text{O}_2$ requires: C:53.07, H: 3.77%.

found: C:52.69, H: 3.82%.

Example 7

(3R,4S)-bis-(3,5-di-tert-butylsalicylideamin)tetrahydropyran-manganese (III) chloride (E7)

- 5 A solution of the ligand (D18) (4.81g, 8.8mmol) in dichloromethane-methanol (1:1, 88ml) was treated with maganese triactate dihydrate (2.35g, 8.8mmol) and the mixture heated at reflux for 4 hours. Lithium chloride (0.56g, 13.2mmol) was added and heating at reflux continued for a further 1 hour. The mixture was cooled, concentrated in vacuo and the residue triturated with diethyl ether (220ml). The solid
10 product was filtered, washed with diethyl ether (2 x 65ml) and dried to afford (5) as a brown powder, 5.3g (94%).

Example 8

- The chiral epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran
15 using (E7) to give (3S,4S)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E8)

- Aqueous sodium hypochlorite (15.24% w/v, 9.8ml, 20mmol) was diluted to 25ml with H₂O. 0.05M NaH₂PO₄(aq) (10ml) was added and the pH adjusted to 11.3. The resulting solution was cooled to 0°C and added to a solution of 2,2-dimethyl-6-
20 pentafluoroethyl-2H-1-benzopyran (2.78g, 10mmol), and the catalyst (E7) (127mg, 0.2mol%) in dichloromethane (10ml). The mixture was stirred at 0°C for 1 hour then allowed to warm to ambient and stirred for a further 18 hours.

- Hexane (100ml) and water (50ml) were added and the organic layer separated. The aqueous phase was washed with hexane (100ml) and the combined organic phase
25 dried over MgSO₄ and concentrated in vacuo to afford a yellow solid (2.60g).

Quantitative hplc analysis showed this to contain 2.47g (84%) of the desired epoxide (E8), identical (¹H nmr, tlc, hplc) with an authentic sample, ee=88.4% by chiral hplc.

30 **Example 9**

(3R,4S)-bis-(3-tert-butyl-5-methylsalicylidenamino)tetrahydropyran-manganese (III) chloride (E9)

- A solution of the ligand (D19) (928mg, 2mmol) in dichloromethane-methanol (1:1, 20ml) was treated with manganese triacetate dihydrate (536mg, 2mmol) and
35 heated at reflux for 3 hours. The mixture was cooled to ambient, lithium chloride (128mg, 3mmol) was added and the solution stirred for 1 hour. The reaction mixture was concentrated in vacuo and the residue triturated with diethyl ether (40ml). The solid product was filtered, washed with diethyl ether (2x15ml) and dried in vacuo to afford the title compound as a brown powder, 1.09g (98%).

Example 10

The chiral epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using (E9) to give (3S,4S)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E8)

Aqueous sodium hypochlorite (15.24% w/v, 9.8ml, 20mmol) was diluted to 25ml with H₂O. 0.05M NaH₂PO₄(aq) (10ml) was added and the pH adjusted to 11.3. The resulting solution was cooled to 0°C and added to a solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (2.78g, 10mmol) and the catalyst (E9) (111mg, 0.2mmol, 2mol%) in dichloromethane (10ml). The mixture was stirred at 0°C for 1 hour then allowed to warm to ambient and stirred for a further 18 hour.

Hexane (100ml) and water (50ml) were added and the organic layer separated. The aqueous phase was washed with hexane (100ml) and the combined organic phase dried over MgSO₄ and concentrated in vacuo to give (E8) as a yellow oil (2.72g, 93%), identical (¹H nmr, tlc, hplc) with an authentic sample, ee=73% by chiral hplc.

Example 11

(3S,4S)-bis-(3,5-di-tert-Butylsalicylideamino)tetrahydrofuran-manganese (III) chloride (E11)

A solution of the ligand (D20) (1.07g, 2mmol) and manganese triacetate dihydrate (536mg, 2mmol) in a mixture of dichloromethane and methanol (1:1, 20ml) was heated at reflux for 6.5 hour. The solution was cooled to ambient, lithium chloride (128mg, 3mmol) was added and the mixture stirred for 16 hours. The reaction mixture was concentrated in vacuo and the residue triturated with diethyl ether (50ml). The solid product was filtered, washed with diethyl ether (2x15ml) and dried in vacuo to afford the title compound as a brown powder, 1.12g (89%).

Example 12

The chiral epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using (E11) to give (3R,4R)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E4)

Aqueous sodium hypochlorite (15.24% w/v, 9.8ml, 20mmol) was diluted to 25ml with H₂O. 0.05M NaH₂PO₄(aq) (10ml) was added and the pH adjusted to 11.3. The resulting solution was cooled to 0°C and added to a solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (2.78g, 10mmol) and the catalyst (E11) (124.5mg, 0.2mmol, 2mol%) in dichloromethane (10ml). The mixture was stirred at 0°C for 1 hour then allowed to warm to ambient and stirred overnight.

Hexane (100ml) and water (50ml) were added and the organic layer separated. The aqueous phase was washed with hexane (100ml) and the combined organic phase dried over MgSO_4 and concentrated in vacuo to a yellow oil, 2.73g.

Quantitative hplc analysis showed this to contain 2.47g (84%) of the desired
5 expoxide (E4), identical (^1H nmr, tlc, hplc) with an authentic sample, ee=85.6% by chiral hplc.

Example 13

(3R,4S)-bis-(3,5-Di-tert-Butylsalicylidenamino)-(2R)-
10 (triphenylmethoxymethyl)tetrahydropyran-manganese (III) chloride (E13)

To the ligand (D24) (160mg, 195 μmol) in dichloromethane-methanol (3:2, 5ml) was added NaOH (0.93ml of 0.417 molar in methanol, 390 μmol) and manganese triacetate dihydrate (52.5mg, 195 μmol). The solution was heated at reflux for 3 hours, lithium chloride (12.5mg, 300 μmol) added and the mixture stirred
15 for 15 hours.

Solvent was removed in vacuo and the residue triturated with diethyl ether (10ml). The solid product was filtered, washed with diethyl ether (2x2ml) and dried with afford the title compound as a brown powder, 136mg (77%).

20 Example 14

The chiral epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using (E13) to give (3S,4S)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E8)

Aqueous sodium hypochlorite (11.4% w/v, 2.6ml, 4mmol) was diluted to 5ml
25 with water. 0.05M NaH_2PO_4 (aq) was added and the pH adjusted to 11.3. The resulting solution was cooled to 0°C and added to a solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (560mg, 2mmol) and the catalyst (E13) (36mg, 0.04mmol) in dichloromethane (2ml) at 0°C. The reaction was stirred for 1 hour at 0°C then at room temperature overnight.

30 Hexane (20ml) and water (10ml) were added and the organic layer separated. The aqueous phase was extracted with further hexane (20ml) and the combined organic phase dried (MgSO_4) and the solvent removed in vacuo to afford (E8) as a yellow oil (0.55g).

Quantitative hplc analysis showed this to contain 0.496g (84%) of the desired
35 epoxide (E8), identical (^1H nmr, tlc, hplc) with an authentic sample, ee=84% by chiral hplc.

Example 15

(-)-trans-1-Benzoyl-3,4-bis(3,5-di-tertbutylsalicylideamino) piperidine-manganese (III) chloride (E15)

5 A mixture of the (-) ligand (D28) (20mg, 0.013mmol) and manganese triacetate dihydrate (10mg, 0.037mmol) in dichloromethane-methanol (3:2, 5ml) was heated at reflux for 4 hour. Lithium chloride (1.6mg, 0.038mmol) was added and reflux continued for a further 1 hour.

Solvent was removed in vacuo and the residue chromatographed on silica (eluent: 10% methanol in dichloromethane) to afford the title compound as a brown powder, 22mg (97%).

10

Example 16

The chiral epoxidation of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran using (E15) to give (3R,4R)-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran (E4)

15 A solution of 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran (560mg, 2mmol) and the catalyst (E15) (22mg, 0.03mmol) in dichloromethane (2ml) was cooled to 0°C. A mixture of aqueous sodium hypochlorite solution (2.6ml of 11.4% w/v, 4mmol) and 0.05M NaH₂PO₄(aq) (2ml, adjusted to pH 11.3) was added, the mixture stirred at 0°C for 1 hour, then allowed to warm to ambient and stirred
20 overnight.


The mixture was diluted with water (10ml) and extracted with hexane (4x20ml). The combined organic phase was washed with water (10ml), dried over Na₂SO₄ and evaporated to afford the desired epoxide, 492mg (83%). Analysis by chiral hplc showed an ee of 77%.

25

CLAIMS

1. A compound of formula (I):

5



n which M is a transition metal ion;

A is a counter-ion if required;

10 r, s and t are independently 0 to 3 such that $r+s+t$ is in the range of 1 to 3:

R^a, R^b, R^c are each independently hydrogen or CH_2OR' where R' is hydrogen or an organic group;

15 B and E are independently oxygen, CH_2 , NR^d in which R^d is alkyl, hydrogen, alkylcarbonyl, or arylcarbonyl or SO_n where n is 0 or an integer 1 or 2, with the proviso that B and E are not simultaneously CH_2 and that when B is oxygen, NR^d or SO_n , then r cannot be 0, and when E is oxygen, NR^d or SO_n , then t cannot be 0;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently hydrogen, alkyl or alkoxy.

- 20 2. A compound according in claim 1 in which M is Mn.

3. A compound according to claim 2 in which Mn is in an oxidation state (II) or (III).


- 25 4. A compound according to claim 1 in which A is chlorine.

5. A compound according to any one of claims 1 to 4 in which s and t are zero, r is 1 and R^a is hydrogen, B is oxygen and E is CH₂; or r, s and t are 1, R^a, R^b and R^c are hydrogen and B and E are both oxygen; or s is zero, r and t are both 1, R^a is

hydrogen or triphenylmethyloxymethylene and R^C is hydrogen, B is oxygen and E is -CH₂-; or r and t are both 1, s is zero, R^a and R^C are hydrogen, B is NR^d where R^d is phenyl carbonyl and E is CH₂.


- 5 6. A compound according to any one of claims 1 to 5 in which R₁ and R₈ are tertiary butyl, R₃ and R₆ are tertiary butyl or methyl and R₂, R₄, R₅ and R₇ are hydrogen.
7. A compound selected from
 - 10 (±) 3,4-bis (3-*tert* Butyl-5-methylsalicylideamino) tetrahydrofuran manganese (III) chloride;
(*S,S*) *trans* 3,4-bis (3-*tert* Butyl-5-methylsalicylideamino)tetrahydrofuran manganese (III) chloride;
Preparation of (*R,R*)-5,6-bis-(3,5-di-*tert*-butylsalicylidenamino)-1,3-dioxepane]-
 - 15 manganese (III) chloride;
(3*R*,4*S*)-bis-(3,5-di-*tert*-butylsalicylideamino)tetrahydropyran-manganese (III) chloride;
(3*R*,4*S*)-bis-(3-*tert*-butyl-5-methylsalicylidenamino)tetrahydropyran-manganese (III) chloride;
 - 20 (3*S*,4*S*)-bis-(3,5-di-*tert*-Butylsalicylideamino)tetrahydrofuran-manganese (III) chloride;
(3*R*,4*S*)-bis-(3,5-Di-*tert*-Butylsalicylidenamino)-(2*R*)-
(triphenylmethoxymethyl)tetrahydropyran-manganese (III) chloride and
(-)-*trans*-1-Benzoyl-3,4-bis(3,5-di-*tert*butylsalicylideamino) piperidine-manganese
 - 25 (III) chloride.
8. A process for the preparation of compounds of formula (I), as defined in claim 1 which comprises forming a transition metal complex of the following compound of formula (II):

30




where variables R_1 to R_{10} , B, E, r, s, t, R^a , R^b and R^c are as defined in relation to formula (I), in claim 1 and thereafter if necessary separating any enantiomers.


- 5 9. A process for the preparation of compounds of formula (II), in claim 1 which comprises condensing sequentially, in any order, a compound of formula (III):



where r, s, t, R^a , R^b and R^c , E, B are as defined in formula (I) and R_{11} and R_{12} independently represent hydrogen or an amine protecting group, providing at least one of R_{11} and R_{12} is hydrogen, with a compound of formula (IV);



and a compound of formula (V), removing any protecting group R_{11} or R_{12} as necessary ;



wherein R_1 to R_{10} are as defined in relation to formula (I), and thereafter as required isolating the required compound including if necessary separating any enantiomers.

5

10. A process for enantioselectively epoxidising a prochiral olefin in the presence of an oxygen source and a chiral catalyst of formula (I) as defined in claim 1.

10

11. A process according to claim 10 in which the prochiral olefin comprises one of the following list of groups as part of its structure: cyclohexene, 5,6-dihydro-2H-pyran, 1,2,5,6-tetrahydropyridine, 1,2,3,4-tetrahydropyridine and 5,6-dihydro-2H-thiopyran.

15

12. A process according to claim 10 or 11 in which the prochiral olefin comprises one of the following list of groups as part of its structure: 1,2-dihydronaphthalene, 2H-chromene, 1,2-dihydroquinoline, 1,2-dihydroisoquinoline and 2H-thiochromene.

20

13. A process according to any one of claims 10 to 12 in which the prochiral olefin is 2,2-dimethyl-6-pentafluoroethyl-2H-1-benzopyran.

14. A process according to claim 13 in which the 2,2-dimethyl-6-pentafluoroethyl-chromene (3S,4S)-epoxide product is subsequently converted to *trans*-6-pentafluoroethyl-3,4-dihydro-2,2-dimethyl-4R-(piperidin-2-on-1-yl)-2H-1-benzopyran-3S-ol.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 93/01666

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 B01J31/18 C07F13/00 C07D303/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 B01J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 14694 (RESEARCH CORPORATION TECHNOLOGIES) 3 October 1991 cited in the application see claims 1,38,53 see page 23, line 2 - line 6 ----	1-4,6-10
X	J. AM. CHEM. SOC. vol. 112, March 1990 pages 2801 - 2803 W. ZANG 'ENANTIOSELECTIVE EPOXYDATION OF UNFUNCTIONALIZED OLEFINS CATALYSED BY (SALEN)MANGANESE COMPLEX' ----	1-3,6, 10,11
X	J. AM. CHEM. SOC. vol. 108, 1986 pages 2309 - 2320 K. SRINIVASAN 'EPOXYDATION OF OLEFINS WITH CATIONIC (SALEN)MN COMPLEXES.' ----- -/-	1,10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

5 November 1993

Date of mailing of the international search report

29.11.93

Name and mailing address of the ISA

European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

THION, M

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 93/01666

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR,A,2 588 265 (INSTITUT FRANCAIS DU PETROLE) 10 April 1987 ----	
A	EP,A,0 023 075 (IMPERIAL CHEMICAL INDUSTRIES) 28 January 1981 -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. al Application No

PCT/GB 93/01666

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9114694	03-10-91	AU-A- 7555391 EP-A- 0521099	21-10-91 07-01-93
FR-A-2588265	10-04-87	NONE	
EP-A-0023075	28-01-81	AU-B- 538001 AU-A- 5858680 JP-C- 1511004 JP-A- 56015245 JP-B- 63062508 US-A- 4344894	26-07-84 15-01-81 09-08-89 14-02-81 02-12-88 17-08-82